While EGFR-PYK2 co-targeting was identified to be synergistic in TNBC, PYK2 may have a larger role in coordinating EGFR and c-MET signalling depending on the cancer types, evident by data showing PYK2 activation was not affected by Gefitinib in lung cancer cells [46]. The gene discussed is MET; the disease is lung cancer.